All terms

    ICH E6(R3) Good Clinical Practice

    ICH Good Clinical Practice revision with Principles and Annex 1 adopted in January 2025 and Annex 2 in June 2026.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

    Definition

    ICH E6(R3) Principles and Annex 1 were adopted at Step 4 on January 6, 2025, with typographical corrections October 24, 2025. Annex 2 was adopted June 3, 2026; the consolidated final guideline is dated June 16, 2026. Step 4 is a recommendation for regional adoption, not a worldwide legal effective date. FDA issued final E6(R3) guidance in September 2025; EU implementation of Principles and Annex 1 is July 23, 2025. Do not infer Annex 2 regional implementation from those earlier dates. Device trials remain subject to applicable device law and ISO 14155 where relevant, not a universal E6 mandate.
    What the regulation says
    ICH E6(R3) Principles and Annex 1 were adopted at Step 4 on January 6, 2025, with typographical corrections October 24, 2025. Annex 2 was adopted June 3, 2026; the consolidated final guideline is dated June 16, 2026. Step 4 is a recommendation for regional adoption, not a worldwide legal effective date. FDA issued final E6(R3) guidance in September 2025; EU implementation of Principles and Annex 1 is July 23, 2025. Do not infer Annex 2 regional implementation from those earlier dates. Device trials remain subject to applicable device law and ISO 14155 where relevant, not a universal E6 mandate.

    What this means in practice

    ICH E6 addresses medicinal-product clinical trials. Device sponsors may use relevant principles, but must assess applicable device investigation requirements and ISO 14155 separately. Regional adoption does not establish a universal mandatory E6 date for devices.

    Examples

    • Illustrative: A MedTech company developing a novel diagnostic device implements a risk-based quality management system for its global clinical trial, aligning with ICH E6(R3)'s principles to ensure data integrity and patient safety.
    • Illustrative: During a decentralized clinical trial for a cardiovascular implant, the sponsor utilizes electronic informed consent and remote monitoring tools, adhering to the updated guidance on digital systems and non-traditional trial designs provided in ICH E6(R3).
    • Illustrative: A clinical research organization updates its standard operating procedures for investigator training and oversight to reflect ICH E6(R3)'s emphasis on robust sponsor-investigator collaboration and clear roles and responsibilities in device studies.
    Common pitfalls
    • •Treating R3 as a minor update, the principles-based structure represents a meaningful shift in how GCP compliance is demonstrated.
    • •Do not drop existing SOP controls merely because R3 is principles-based; evaluate applicable regional requirements and document justified revisions.
    • •Assuming regional adoption of Principles and Annex 1 also establishes Annex 2 implementation. Check the regional regulator and the applicable clinical-trial requirements separately.

    Frequently asked questions

    ICH E6(R3) Principles and Annex 1 were adopted at Step 4 on January 6, 2025, with typographical corrections October 24, 2025. Annex 2 was adopted June 3, 2026; the consolidated final guideline is dated June 16, 2026. Step 4 is a recommendation for regional adoption, not a worldwide legal effective date. FDA issued final E6(R3) guidance in September 2025; EU implementation of Principles and Annex 1 is July 23, 2025. Do not infer Annex 2 regional implementation from those earlier dates. Device trials remain subject to applicable device law and ISO 14155 where relevant, not a universal E6 mandate.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Latest in MedTech

    Sources

    7 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Official-source claim check:

    Principles and Annex 1 reached Step 4 January 6, 2025; Annex 2 June 3, 2026; consolidated version June 16, 2026. Regional implementation is separate.

    Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.

    Remaining verification limits
    • Original merged record reviewed in full. Illustrative examples are hypothetical, not verified case histories. Evidence supports the specific propositions below, not an assertion that every linked page verifies all merged content.
    Tier 2Regulator guidance and consensus· 7
    Link health: 3 verified 4 unchecked· last checked 2026-06-20
    ICH·3FDA·2AAMI·1EMA·1
    1. 1
      ICH E6(R3) Guideline
      Tier 2 Verified
      ICHich.org
    2. 2
      FDA Implementation of ICH E6(R3)
      Tier 2 Verified
      FDAfda.gov
    3. 3
      AAMI Standards
      Tier 2 Verified
      AAMIaami.org
    4. 4
      ICH consolidated final E6(R3), June 2026
      Tier 2 Unchecked
      ICHdatabase.ich.org
    5. 5
      ICH adoption chronology
      Tier 2 Unchecked
      ICHich.org
    6. 6
      FDA September 2025 final guidance
      Tier 2 Unchecked
      FDAfda.gov
    7. 7
      EMA E6 implementation
      Tier 2 Unchecked
      EMAema.europa.eu

    Inline markers like [1] jump to the matching reference above.